摘要
目的:评价昔布类药物的临床安全性。方法:综述近年来国内外关于昔布类药物临床安全性的文献与报道,分别对全球已上市的六种昔布类药物进行安全性评价。结果:昔布类药物有增加心血管事件的风险,但它们的类效应强度不同,合理选择使用利大于弊。
出处
《黑龙江医药》
CAS
2009年第6期875-876,共2页
Heilongjiang Medicine journal
参考文献8
-
1杨晓燕,龚培力,傅鹰,曾繁典.非甾体抗炎药的临床安全性再评价[J].药物流行病学杂志,2005,14(6):363-367. 被引量:9
-
2Hermann M;Shaw S.Selective COX-2 inhibitons and renal injury in salt-sentitive hypertension[J],2005(02).
-
3White WB.Companion of thrombomlolie events in patients treatde with celecoxib.a cyelonxygenade-2 specific inhibitor,verse ibuprofen or dislofesure[J]American Journal of Cardiology.
-
4龚培力,杨晓燕,曾繁典,傅鹰.非甾体抗炎药存在的安全性问题——FDA的声明及各国的反应[J].药物流行病学杂志,2005,14(3):172-175. 被引量:10
-
5崔露阳.研究显示依托考昔耐受性良好[J]国家发改委医药工业信息中心站,2004.
-
6Bresalier RS;Sundler RS.Cardiovascular events associated with refecoxib in a ruloretal adenoxita ehemophevention trial[J],2005(11).
-
7Bomhardier C;Laine L.Comparison of upper gastrointestinal toxicity of rufecoxib and naproxen in patients with rheumatoxid ar-thritie[J],2000(21).
-
8杨景勋.万络事件及COX-2抑制剂心血管安全性的最新评估[J].药物不良反应杂志,2005,7(2):150-154. 被引量:18
二级参考文献33
-
1FDA announces a series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs). www. fda.gov/bbs/topics/news/2005/NEW01171. html , 2005-04-07/2005 -05.
-
2COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). www. fda. gov/cder/drug/infopage/ COX2/ default. htm ,2005-04-07/2005-05.
-
3Questions and Answers: FDA Regulatory Actions for the COX-2 Selective and Non-Selective Non-Steroidal Anti-inflammatory drugs ( NSAIDs ) . www. fda. gov/cder/drug/infopage/ COX2/ CO X2qa. htm ,2005-04-07/2005-05.
-
4FDA Public Health Advisory: FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs(NSAIDs ). www. fda. gov/cder/drug/advisory/COX2. htm,2005 -04-07/2005 -05.
-
5.国家食品药品监督管理局密切关注非甾体类抗炎药物的安全性问题[EB/OL].http://www.sfda.gov.cn/cmsweb/webportal/W1/search. html,2005-04-12/2005-05.
-
6European Medicines Agency announces regulatory action on COX-2 inhibitors. http ://www. emea. eu. int/htms/hotpress/d6275705. htm, 2005-04-17/2005-05.
-
7European Medicines Agency statement on the suspension of use of Bextra. http://www. emea. eu. int/htms/hotpress/h12163705. htm, 2005-04-12/2005-05.
-
8Media Releases Stringent Conditions for COX-2 Inhibitors.http ://www. medsafe. govt. hz/hot/media/2005/COX2April05. htm, 2005-04 -29/2005-05.
-
9Health Canada has asked Pfizer to suspend sales of its drug BextraTM and informs canadians of new restrictions on the use of Celebrex (R). http://www. hc-sc. gc. ca/english/media/releases/2005 / statement_drug_safety. html , 2005-04-07/2005-05.
-
10Expanded information on Cox-2 inhibitors for doctors and pharmacists (amended * ). http://www. tga. gov. au/media/2005/050214_cox2. htm#pdf , 2005-04-14/2005-05.
共引文献31
-
1傅鹰,龚培力,杨晓燕,曾繁典.非甾体抗炎药心血管不良反应证据评估和处理程序分析[J].药物流行病学杂志,2005,14(4):201-204. 被引量:2
-
2傅鹰,吴方建.美国非甾体抗炎药安全措施在我国非期刊媒体传播情况的调查[J].中国药师,2006,9(2):157-158.
-
3曾翼,徐进宜,吴晓明,华维一.选择性环氧合酶-2抑制剂的研究现状及进展[J].中国新药杂志,2006,15(6):410-415. 被引量:2
-
4潘献柱,汪思应,王林,程洁.选择性COX-2抑制剂的用药风险与新功用[J].药学进展,2006,30(4):165-170. 被引量:3
-
5秦利荣,钱珊珊.2002-2004年南京地区非甾体抗炎药应用分析[J].中国药师,2006,9(5):479-480. 被引量:1
-
6李小明,胡爱虹.“万络事件”引发的非甾体类抗炎药的再评价[J].实用药物与临床,2006,9(3):179-180. 被引量:4
-
7赵延斌.从罗非昔布事件谈非甾体抗炎药物的安全性[J].中国药师,2006,9(7):658-659. 被引量:1
-
8温晓娜,毛静怡.非甾体抗炎药的不良反应[J].中国药师,2006,9(10):959-960. 被引量:24
-
9董晓春,汪培山.环氧化酶-2抑制药的心血管安全性研究现况[J].药物流行病学杂志,2006,15(5):283-288. 被引量:9
-
10许慧君,张兰桐.非甾体抗炎药的研究进展及其不良反应[J].河北医科大学学报,2007,28(1):73-75. 被引量:12
同被引文献17
-
1Bombardier C,Laine L,Reicin A,et al.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.VIGOR Study Group[J].N Engl J Med,2000,343(21):1520.
-
2Winkelmayer WC,Waikar SS,Mogun H,et al.Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury[J].Am J Med,2008,121(12):1092.
-
3Brune K,Hinz B.Selective cyclooxygenase-2 inhibitors:similarities and differences[J].Scand J Rheumatol,2004,33(1):1.
-
4McAdam BF,Catella-Lawson F,MardinilA,et al.Systemic biosynthesis of prostacyclin by cyclooxygenase(COX)-2:the human pharmacology of a selective inhibitor of COX-2[J].Proc Nati Acad Sci USA,1999,96(1):272.
-
5Scheiman JM,Yeomans ND,Talley NJ,et al.Prevention of ulcers by esomeprazole in at risk patients using nonselective NSAIDs and COX-2 inhibitors[J].Am J Gastroenterol,2006,101(4):701.
-
6Nussmeier NA,Whelton AA,Brown MT,et al.Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery[J].N Enql J Med,2005,352(11):108.
-
7Paech MJ,Salman S,Llett KF,et al.Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery:a comparison of naive pooled data analysis and nonlinear mixed-effects modeling[J].Anesth Analg,2012,114(4):837.
-
8White WB,West CR,Borer JS,et al.Risk of cardiovascular events in patients receiving celecoxib:a metaanalysis of randomized clinical trials[J].Am J Cardiol,2007,99(1):91.
-
9Sakamoto C,Soen S.Efficacy and safety of the selective cyclooxygenase-2inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan[J].Digestion,2011,83(l-2):108.
-
10Trelle S,Reichenbach S,Wandel S,et al.Cardiovascular safety of non-steroidal anti-inflammatory drugs:network meta-analysis[J].BMJ,2011,342:c7086.
二级引证文献5
-
1李士洋,夏良友,李宇琛,李龙飞,陈鸿雨,何丹婷,卜仕金.维他昔布片对猫血液学指标的影响研究[J].中国兽药杂志,2017,51(5):48-52. 被引量:2
-
2王欣,张晓乐,胡跃林,谢兴.不同镇痛药物对下肢关节镜术后的镇痛效果观察[J].中华骨与关节外科杂志,2018,11(5):378-381. 被引量:2
-
3王芳,李小东,任心慈,桑翩翩,许静语,钱文.我院注射用帕瑞昔布钠药物利用评价标准的建立与应用[J].中国药师,2020,23(10):1974-1977. 被引量:6
-
4张国磊,张哲敏,段文旭,王丰羽.选择性COX-2抑制剂在手屈肌腱损伤围手术期的应用[J].河北医药,2021,43(8):1192-1195. 被引量:3
-
5汪国玉,黄玲玲,朱文靖,陈美玲,冯晓俊,王君萍.我院注射用帕瑞昔布钠临床应用的干预效果分析[J].海峡药学,2024,36(5):68-72.
-
1黄英英,陈劲松,周淑冷.拉米夫定致精神障碍1例[J].中国新药与临床杂志,2003,22(10):638-639. 被引量:11
-
2吴敬华,钟炎.昔布类药物对于心血管内科的风险评估[J].中国社区医师,2016,32(11):29-30. 被引量:1
-
3郭宗儒,王汝龙.昔布类药物临床药学新进展[J].临床药物治疗杂志,2008,6(5):1-5.
-
4顾一珠,马平,王在震.塞来昔布衍生物SY3-1抗炎活性的初步研究[J].山东大学学报(医学版),2007,45(6):646-647.
-
5裴振峨.昔布类药物的心血管风险评价[J].临床药物治疗杂志,2008,6(5):59-62.
-
6郭胜杰,窦广宏.昔布类药物的临床安全性[J].中国实用医药,2011,6(11):199-200. 被引量:1
-
7郭胜杰,窦广宏.昔布类药物的临床安全性[J].中国实用医药,2010,5(36):239-239. 被引量:2
-
8刘昕.英语加油站[J].中国执业药师,2007(7):50-50.
-
9EMEA对昔布类药物加强安全管制[J].药学进展,2005,29(5):240-240.
-
10刘卫东.昔布类药物临床安全性探讨[J].中国乡村医药,2015,22(12):85-87. 被引量:5